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We aimed to investigate risk factors of local and distant recurrence in small-sized, node negative breast cancer in women <35 
years in a Chinese cohort. Between January 1994 and January 2007, 107 patients with pathologically confirmed small-sized 
(1 cm), node negative breast cancer who did not receive neoadjuvant or adjuvant chemotherapy were included. The 5-year 
recurrence-free survival (RFS) was estimated according to different prognostic variables. With a median time of 60 months 
(range, 8–60 months) follow-up, local and distant recurrence were observed in 25 cases (23.4%). By univariate analysis, 
HER-2 positivity, triple negative (TN), and high Ki-67 index (14%) were risk factors of a lower RFS (hazard ratio (HR) 
6.680, 95% confidence interval (CI) 2.350–18.985, P<0.0001 for HER-2 positive; HR 4.769, 95%CI 1.559–14.591, P=0.006 
for TN; HR 6.030, 95%CI 2.659–13.674, P<0.0001 for high Ki-67 index). Patients with grade 3 tumors had a lower RFS (HR 
2.922, 95%CI 1.096–7.791, P=0.032) compared with those with grade 1 or grade 2 tumors. By multivariate analysis, HER-2 
positivity (HR 10.204, 95%CI 3.391–30.704, P<0.0001), TN (HR 10.521, 95% CI 3.152–35.113, P<0.0001) and high Ki-67 
index (HR 10.820, 95%CI 4.338–27.002, P<0.0001) remained risk factors of RFS. In this cohort, HER-2 positivity, triple neg-
ative and high Ki-67 index were independent risk factors of RFS in young patients with T1a,bN0 breast cancer. Subsequent 
pregnancy did not affect RFS. 
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Breast cancer is the most common malignant tumor in 
women worldwide. Because of the increased use of screen-
ing mammography, the incidence of early stage breast can-
cer is increasing internationally [1–3]. The prognosis of 
small-sized (1 cm), node-negative breast cancer is gener-
ally considered to be excellent even without systemic adju-
vant therapy [4]. Nevertheless, certain subgroups of patients 
who are initially diagnosed with small, node-negative breast 
cancer have a risk of recurrence. One of the most important 
challenges that clinicians must face in the treatment of early 
breast cancer is how to distinguish those patients who will 
need additional systemic therapy from those patients who 
will not.  
Some studies have identified high risk group for recur-
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rence in node-negative patients with 1 cm invasive breast 
cancer, and determined which patients are at the greatest 
risk and may benefit from adjuvant treatment. However, the 
results are not consistent, and few include Chinese popula-
tions. 
Young women diagnosed with breast cancer have a 
worse disease-free survival and breast cancer specific sur-
vival than postmenopausal women. Several retrospective 
studies have evaluated age and prognosis; some found that 
young patients have a significantly higher rate of recurrence 
compared with their older counterpart [5,6]. Kwon et al. [5] 
found that age younger than 35 is an independent risk factor 
of recurrence, even in patients with node-negative breast 
cancer of 1 cm. Therefore, young age of less than 35 years 
should be regarded as a poor prognostic factor when adju-
vant therapy is considered. This is important, especially for 
Asian patients, because the proportion of young women in 
Asian countries is higher than that in Western countries 
[7,8]. 
As most authors have confirmed that age younger than 
35 is an independent risk factor. We narrowed our analyses 
to T1N0M0 patients younger than 35 years to investigate 
which factors influence the outcome of this special group 
hoping to provide more information to guide individualized 
therapy in this controversial area.  
Since the average age of women giving birth for the first 
time is increasing, many young patients diagnosed with 
breast cancer have not started or completed their family 
planning. Thus, gynecologists and oncologists are con-
fronted more often with the question of childbearing after 
breast cancer. Pregnancy after a diagnosis of early stage 
breast cancer does not appear to increase the risk of relapse 
[9]. A recent meta-analysis done by Azim et al. [10] sug-
gested that pregnancy after a diagnosis of breast cancer is 
associated with improved survival when compared with 
breast cancer patients that do not have a pregnancy after 
their diagnosis. To date, no study has analyzed the impact of 
subsequent pregnancy on recurrence-free survival (RFS) in 
small-sized (1 cm), node-negative breast cancer, thus we 
address this issue in the present article. 
1  Methods 
1.1  Patients  
We conducted a retrospective analysis of medical records of 
the patients with pathologically confirmed invasive breast 
cancer who had received curative surgery at the Third Af-
filiated Hospital of Harbin Medical University, the Fourth 
Affiliated Hospital of Harbin Medical University, or the 
First Affiliated Hospital of Xinxiang Medical College from 
January 1994 to January 2007. Eligibility criteria included 
complete surgical resection, histological diagnosis of inva-
sive ductal carcinoma of 1 cm or less (T1a, T1b), no lymph 
node metastasis (N0), no lymphatic invasion and no venous 
invasion according to the 6th edition of the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual [11]. 
The number of patients with T1mic tumors was so small that 
we could not include this group in our analysis. Patients 
with a history of previous malignancy of the breast or other 
sites and those who received neoadjuvant or adjuvant 
chemotherapy were excluded. 
1.2  Clinical and biological data acquisition 
Data on patient characteristics, type of operation and axil-
lary lymph node examinations were collected. The type of 
operation was divided into mastectomy and breast conserv-
ing surgery (BCS). Pathologic information was obtained by 
two pathologists by reviewing pathology reports on the fol-
lowing variables: tumor size, histological subtype, modified 
Bloom-Richardson histological grade, lymphatic invasion, 
venous invasion and tumor border. Immunohistochemical 
data for standard prognostic biomarkers (ER, PR, HER-2) 
were also collected. For ER and PR, cases with 1% or more 
positive staining were considered positive. For HER-2, 3+ 
staining by immunohistochemistry or positivity by fluores-
cence in situ hybridization (FISH) was considered positive. 
Because most patients in our study did not have Ki-67 
analysis and those with Ki-67 reports had used the old 
standard, we checked paraffin embedded tissue for Ki-67 
and defined the high Ki-67 index using the latest standard 
(14% or more positive staining as a high index) [12]. Sub-
sequent pregnancy status of all patients was checked.  
1.3  Statistical analysis 
The median follow-up duration was 60 months (range, 8–60 
months). RFS was from the date of curative surgery to the 
date when breast cancer recurred irrespective of locoregion-
al or distant metastases including ipsilateral and contrala-
teral breast recurrences or the last follow-up. RFS was esti-
mated by the Kaplan-Meier method. The log-rank test was 
used for a comparison of the survival curves between sub-
groups according to prognostic factors. Cox proportional 
hazards model was used to determine association of breast 
cancer subtypes with other covariates. P-value <0.05 was 
considered significant. 
All statistical analyses were performed using SPSS for 
Windows software, version 19.0 (SPSS Inc, Chicago, IL). 
2  Results 
We identified 159 patients with a primary tumor size of   
1 cm or less and age <35 years. After excluding 47 patients 
who received neoadjuvant or adjuvant chemotherapy, 3 pa-
tients lost to follow-up and 2 patients who died from other 
reasons (not related to tumor), 107 patients were included in 
the analysis.  
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Patient characteristics are shown in Table 1. The median 
age at diagnosis of this cohort was 32 years (range, 19–34 
years), of which 27 (25.2%) were younger than 30 years and 
80 (74.8%) were in the 30 and <35 years group. Of the 107 
patients, 34, 45 and 28 had grade 1, 2 and 3 tumors, respec-
tively. As for cancer type, 58 (54.2%) patients had hormone 
receptor (HR) positive tumors (ER+ and/or PR+/ 
HER2+,), 26 (24.3%) had HER-2 positive tumors 
(HER-2/ER/PR), and 23 (21.5%) had triple negative 
breast cancer (TNBC) (ER/PR/HER-2). As for the tu-
mor stage, 50 (46.7%) and 57 (53.3%) had T1a and T1b tu-
mors, respectively. Regarding treatment, 95 (88.8%) pa-
tients underwent mastectomy and 12 (11.2%) patients re-
ceived BCS+radiotherapy. There was no difference in sur-
gery choice between T1a and T1b groups. In Ki-67 analysis, 
30 (28%) patients had a high Ki-67 index while 77 (72%) 
patients had a low Ki-67 index. Almost all patients (86.2%) 
with HR positive tumors received adjuvant hormonal ther-
apy. Subsequent pregnancy was found in 13 (12.1%) pa-
tients. Table 2 shows the 5 year RFS by different character-
istics and HR value of different risk factors according to  
univariate analysis. 
By univariate analysis, HER-2 positivity, TN and high 
Ki-67 index (14%) were risk factors of a lower RFS (HR 
6.680, 95%CI 2.350–18.985, P<0.0001 for HER-2 positive; 
HR 4.769, 95%CI 1.559–14.591, P=0.006 for TN; HR 
6.030, 95%CI 2.659–13.674, P<0.0001 for high Ki-67 in-
dex). Patients with grade 3 tumors had a lower RFS (HR 
2.922, 95%CI 1.096–7.791, P=0.032) compared with those 
with grade 1 or grade 2 tumors. Age (<30 years versus 30 
years), tumor size (T1a versus T1b), treatment mode and sub-
sequent pregnancy did not affect RFS in this cohort. Dif-
ferences in RFS by different pathological subtype, Ki-67 
index and grade groups are shown in Figures 1, 2, and 3, 
respectively. 
By multivariate analysis, HER-2 positive (HR 10.204, 
95%CI 3.391–30.704, P<0.0001), TN (HR 10.521, 95%CI 
3.152–35.113, P<0.0001) and high Ki-67 index (HR 10.820, 
95%CI 4.338–27.002, P<0.0001) remained risk factors of 
RFS. Grade 3 did not reach statistical significance (HR 
2.129, 95% CI 0.776–5.837, P=0.142). Results of multivar-
iate analysis are shown in Table 3. 
Table 1  Distribution of 107 breast cancer cases according to selected individual characteristics 
Characteristics n % 
Age at diagnosis   
<30 27 25.2 
30 and <35 80 74.8 
T   
T1a 50 46.7 
T1b 57 53.3 
Grade   
1 34 31.8 
2 45 42.1 
3 28 26.1 
Breast cancer subtypesa)   
HR+ (ER+ and/or PR+/HER-2+,) 58 54.2 
HER-2+ (HER-2+/ER/PR) 26 24.3 
TNBC (ER/PR/HER-2) 23 21.5 
Surgery   
Mastectomy 95 88.8 
BCS+RTb) 12 11.2 
Adjuvant hormonal therapy (HT)   
None 8 13.8 
HT 50 86.2 
Ki-67   
<14% 77 72.0 
14% 30 28.0 
Subsequent pregnancy   
No 94 87.9 
Yes 13 12.1 
a) ER, estrogen receptor; PR, progesterone receptor; HER-2+, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; b) 
BCS+RT, breast conserving surgery+radiotherapy. 
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Table 2  Five years recurrence-free survival by different characteristics and HR value of different risk factors in univariate analysisa) 
Characteristics Patients at risk (n) Recurrence (n) P HR (95% CI) 
Age at diagnosis     
<30 27 8   
30 and <35 80 17 0.398 0.696 (0.3001.613) 
T     
T1a 50 11   
T1b 57 14 0.674 1.185 (0.5382.610) 
Grade     
1 34 6   
2 45 7 0.763 0.845 (0.2842.516) 
3 28 12 0.032 2.922 (1.0967.791) 
Breast cancer subtypes     
HR+ (ER+ and/or PR+/HER-2+,) 58 5   
HER-2+ (HER-2+/ER/PR) 26 12 <0.0001 6.680 (2.35018.985) 
TNBC (ER/PR/HER-2) 23 8 0.006 4.769 (1.55914.591) 
Surgery     
Mastectomy 95 20   
BCS+RT 12 5 0.192 1.922 (0.7215.123) 
Adjuvant hormonal therapy (HT)     
None 8 1   
HT 50 4 0.677 0.627 (0.0705.616) 
Ki-67     
<14% 77 9   
14% 30 16 <0.0001 6.030 (2.65913.674) 
Subsequent pregnancy     
No 94 21   
Yes 13 4 0.464 1.492 (0.5124.347) 
a) Abbreviations as in Table 1. 
Table 3  Multivariate analysis results 
Variables HRa) (95%CIb)) P 
HER-2 positive 10.204 (3.391–30.704) <0.0001 
Triple negative 10.521 (3.152–35.113) <0.0001 
High Ki-67 (14%) 10.820 (4.338–27.002) <0.0001 
Grade 3 2.129 (0.776–5.837) 0.142 
a) HR, hazard ratio; b) CI, confidence interval. 
 
 
Figure 1  Five years recurrence-free survival by different breast cancer 
subtype. 
 
Figure 2  Five years recurrence-free survival by different Ki-67 index. 
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Figure 3  Five years recurrence-free survival by different histologic 
grade. 
3  Discussion 
In the present study, we found that there was no difference 
in RFS between mastectomy and BCS+radiotherapy groups. 
This is consistent with a retrospective study of Moroccan 
young women by Abahssain et al. [13]. Although the 
NCCN guidelines refer to age <35 years as a relative con-
traindication for BCS, BCS+radiotherapy seems to be a 
reasonable local treatment choice for early breast cancer in 
patients <35 years. The reason for this is probably because 
our research subjects were patients with small tumors and 
small-sized (1 cm), node-negative breast cancer. This is a 
special group which has been reported to have an excellent 
prognosis [4]. Prospective studies are needed to evaluate the 
role of BCS in patients <35 years. 
According to the 2010 National Comprehensive Cancer 
Network Guidelines, small tumors (those less than 0.5 cm in 
greatest diameter (T1a) that do not involve the lymph nodes 
are so favorable that adjuvant systemic therapy is of mini-
mal benefit and is not recommended. These guidelines also 
state that patients with invasive breast cancer 0.61 cm in 
diameter and no lymph node involvement (T1b) may be di-
vided into patients with a low risk of recurrence and those 
with unfavorable prognostic features (intramammary angi-
olymphatic invasion, high nuclear grade, high histological 
grades, HER-2 positive status, HR negative status) warrant 
consideration for adjuvant chemotherapy [14].  
Studies have shown that certain biologic subtypes, in-
cluding HER-2 positive and TNBC tumors, have an in-
creased risk of relapse, despite their small size, even less 
than 0.5 cm in greatest diameter (T1a) [1519]. The present 
study showed that HER-2 positivity and TN status were 
correlated with worse RFS. There were no RFS differences 
between the T1a and T1b groups. Patients who have HER-2 
positive or triple negative early breast cancer may need ad-
juvant chemotherapy, even with tumors of less than 0.5 cm 
in size (T1a). We also identified that grade was an inde-
pendent risk factor in the univariate analysis, but it did not 
reach statistical significance in the multivariate analysis. 
This is consistent with results of Kwon et al. [5] and Albert 
et al. [17]. Some authors reported that a high grade of tumor 
is associated with a high relapse or mortality rate [2022]. 
The influence of tumor grade on outcome needs further in-
vestigation. 
The results on Ki-67 as a risk factor of local recurrence 
show discrepancy. Kwon et al. [5] pointed out that Ki-67 
did not affect RFS, while Colleoni et al., in a study of 425 
patients, found that in both univariate and multivariate 
analyses the most relevant prognostic factor of local and 
distant relapse for this low-risk population was Ki-67 label-
ing [23]. The reason for this discrepancy is possibly that 
they used a different standard for the high Ki-67 index 
(Kwon et al. used 10% while Colleoni et al. used 20% of 
the cells as the high ki-67 index). To our knowledge, we are 
the first to investigate Ki-67 as a risk factor of RFS in this 
special group using the latest standard (14% of the cells as 
high Ki-67 index). We found that Ki-67 was also an inde-
pendent risk factor of RFS. For patients with a high Ki-67 
index and even for HR positive patients, chemotherapy 
should be considered.  
In the present study, we found no difference in RFS in 
the pregnancy and non-pregnancy groups. Young patients 
who have not started or completed their family planning 
may have a strong desire to have a child, especially for 
those with early stage breast cancer. To our knowledge, we 
are the first to investigate the impact of subsequent preg-
nancy on RFS in small-sized (1 cm), node-negative breast 
cancer and our result may help to give such patients confi-
dence to become a mother after the diagnosis of breast can-
cer. 
The role of trastuzumab (Herceptin) in early stage Her-2 
positive breast cancer in young women is of great im-
portance. Herceptin is usually used together with chemo-
therapy. Because we chose patients who did not receive 
chemotherapy for the current study, we can not address this 
issue. 
In our cohort, most HR positive patients received adju-
vant hormonal therapy which is the routine treatment for 
such patients. Adjuvant hormonal therapy was analyzed as 
an independent risk factor in the univariate analysis; how-
ever, it did not seem to influence RFS. The reason for this 
may be the relatively small size of this subgroup. Also, our 
follow-up time was only 60 months and the recurrence rate 
in the early stage HR positive group is very low even with-
out adjuvant hormonal therapy. To investigate this question, 
we need to expand the sample size and prolong the follow- 
up time. 
Several limitations of this study should be considered 
when interpreting the results. First, this is a retrospective 
study which lends inherent bias. Second, we used the path- 
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ological data of different institutions in the analysis and this 
may lead to bias because of differing quality-control proce-
dures in different hospitals even though we investigated all 
of the pathological results by two pathologists. 
4  Conclusion 
In practice, many early stage breast cancer patients receive 
chemotherapy simply because they are younger than 35 
years. However, some patients with a good prognosis may 
not need chemotherapy. In the present study, we identified 
that HER-2 positivity, TNBC and high Ki-67 were inde-
pendent risk factors for RFS in young small-sized (1 cm), 
node-negative breast cancer patients. Patients with HER-2 
positivity, TNBC and high Ki-67 tumors should be consid-
ered to receive chemotherapy. BCS+radiotherapy may be a 
reasonable local treatment choice for early breast cancer 
patients even for those aged <35 years, although this needs 
further confirmation. There is no difference in RFS between 
the very young (<30 years) and the young (30 and <35 
years). T1a and T1b have no difference in RFS, so we need 
not treat them differently. Subsequent pregnancy and adju-
vant hormonal therapy may not affect RFS in young early 
stage breast cancer patients although confirmation will be 
necessary by a large sample study. 
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